A new way to recover from hypos — combining fast carbs with adaptive energy for complete recovery
Klario is designed to bypass the brain’s energy bottleneck using adaptive energy with fast carbs
Developed by leading diabetes specialists and studied across 1000+ real-world hypos
In studies: Klario delivered 27% fewer recurrent hypos and got 75% back to their day faster
Klario has been analyzed in a randomized clinical study of hypos in adults with T1D
fewer repeat lows in the 2 hours after treating a hypo
less time in glucose highs and lows per week
Randomised crossover vs glucose · 12 adults with type 1 diabetes · Russell-Jones et al. Diabetes, Obesity and Metabolism 2026
Real-world improvements in how people feel and function after a hypo with Klario
Got back to their day faster
Never/rarely had a hangover
Felt more in control
“I usually have a crash pattern where you go up and down all day — I haven’t had that with Klario.”
“The fatigue and brain fog definitely improved. It made a huge difference at work; I could actually go about my day instead of being written off.”
Beyond numbers on a graph, people in the study told us Klario helped them feel and function better after a hypo
During a hypo, your brain runs low on its usual fuel—glucose. Even after levels return to normal, it may struggle to use that glucose efficiently, creating an ‘energy bottleneck’ that can leave you feeling wiped out and foggy.
Klario contains 15g of fast‑acting carbohydrate to raise blood sugar, just like standard treatments
It also provides adaptive energy that the brain can use through different pathways when glucose use is limited
Bypassing the energy bottleneck, Klario fuels the brain directly, helping reduce brain fog and the “hypo hangover”
Your body’s built-in backup fuel system—activated when glucose runs low, helping keep your brain and body functioning.
BHB is one example. Produced by the liver, it rises during fasting, or intense exercise—and provides an additional energy source when glucose alone isn’t enough.
The Klario clinical program was led by Prof. Russell‑Jones, leading clinician with extensive experience in type 1 diabetes research
“Klario offers a new way to support recovery – not just correcting the CGM number, but helping people feel and function better afterwards.”
Professor David Russell-Jones
Principal Investigator
We’re continuing to explore how Klario can better support people living with diabetes through future research. Register your interest below and we’ll contact you when a relevant study opens.
Register for our upcoming survey on the real-world impact of hypos, including recovery, the hypo hangover, and challenges during exercise
“Tell me when there are studies on using Klario around exercise and sport.”
“Tell me when there are studies on using Klario during night‑time hypos.”
Discover why 100% of our clinical trial participants said they would recommend Klario to others
Klario is built on rigorous clinical research, combining fast-acting carbohydrates with adaptive energy to support more complete recovery after hypoglycaemia.
Our studies explore objective CGM data, real-world outcomes and underlying metabolic mechanisms — helping explain not just that Klario works, but why.
A randomised, crossover clinical study assessing effectiveness of Klario for recovery from hypoglycaemia compared with standard glucose treatment in adults with type 1 diabetes.
Read paperAn independent expert commentary described Klario as a “potential new standard of care” for hypoglycaemia recovery and highlighted its potential to improve management beyond glucose alone.
Read paperA peer-reviewed expert commentary outlines a “brain energy bottleneck” during and after hypoglycaemia, providing a mechanistic explanation for delayed recovery despite normalised glucose levels.
Read paperA clinical study demonstrated that Klario provides a more stable energy profile than glucose alone, supporting faster symptom relief and improved return to daily activity [presented as conference abstract].
Patient-reported outcomes from a randomised study showed that Klario improved recovery experience, with most participants reporting faster recovery, reduced fatigue, and greater confidence in managing hypoglycaemia [presented as conference abstract].
A structured patient-led assessment exploring real-world limitations of current glucose-only treatments for treatment-related hypoglycaemia in adults with type 1 diabetes. Findings informed Klario product development decisions [presented as conference abstract].
